Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 1, 2024Journal of Clinical Oncology

Efficacy of carfilzomib-based regimens as induction/consolidation therapy in newly diagnosed multiple myeloma: A meta-analysis.

View Full Paper
Ask AI
Bookmark
Share

Authors

WAWajeeha AimanRoswell Park Comprehensive Cancer CenterMAMuhammad Ashar AliAllegheny Health NetworkRURana Muhammad Usman

Discussion

Loading...

Member takes

Implication

Meta-analysis demonstrates high response and survival rates with four-drug carfilzomib regimens in newly diagnosed multiple myeloma, suggesting viable alternatives to stem cell transplant.

Key Points

  • Four-drug carfilzomib combinations achieve superior response and survival outcomes in newly diagnosed multiple myeloma, matching efficacy observed with autologous stem cell transplant.
  • Minimal residual disease negativity reached 80% with carfilzomib quadruplets and transplant, while isatuximab-based combinations attained a 79% rate without requiring transplantation.
  • Meta-analysis of 25 trials demonstrates potent proteosome inhibitor combinations provide effective non-transplant options, though extended follow-up is needed to verify durability.

Cite This Study

Aiman et al. (2024) studied this question.

synapsesocial.com/papers/68e67069b6db6435875fb223https://doi.org/10.1200/jco.2024.42.16_suppl.e19535
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical efficacy and safety of daratumumab-carfilzomib based therapy in newly diagnosed multiple myeloma: A retrospective cohort analysis2025
  2. 2Safety and efficacy of carfilzomib-based combinations in relapsed/refractory multiple myeloma patients in a real-world Setting : Results of a french single academic center retrospective study.2025
  3. 3Real-world efficacy and safety of the carfilzomib–pomalidomide–dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study2026
  4. 4Efficacy and Toxicity Profile of Carfilzomib-Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review2021 · 10 citations
  5. 5Superior outcomes and high-risk features with carfilzomib, lenalidomide, and dexamethasone combination therapy for patients with relapsed and refractory multiple myeloma: results of the multicenter KMMWP2201 study2024 · 5 citations